The DOI matches its Crossref record; 560 of the 560 references it cites were found in a registry or an index.
Antibody Structure and Function: The Basis for Engineering Therapeutics
Open accessAbstract
Antibodies and antibody-derived macromolecules have established themselves as the mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure–function relationships of antibodies provides a platform for protein engineering that has been exploited to generate a wide range of biologics for a host of therapeutic indications. In this review, our basic understanding of the antibody structure is described along with how that knowledge has leveraged the engineering of antibody and antibody-related therapeutics having the appropriate antigen affinity, effector function, and biophysical properties. The platforms examined include the development of antibodies, antibody fragments, bispecific antibody, and antibody fusion products, whose efficacy and manufacturability can be improved via humanization, affinity modulation, and stability enhancement. We also review the design and selection of binding arms, and avidity modulation. Different strategies of preparing bispecific and multispecific molecules for an array of therapeutic applications are included.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–560 of 560
i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4
Griffiths, K. R., Dolezal, O., Cao, B., Nilsson, S. K., See, H. B., Pfleger, K. D. G., Roche, M., Gorry, P. R., Pow, A., Viduka, K., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.721050 · Cited by 66
Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers
Arezumand, R., Alibakhshi, A., Ranjbari, J., Ramazani, A., & Muyldermans, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01746 · Cited by 66
Yang, R., Jain, T. S., Lynaugh, H., Nobrega, R. P., Lu, X., Boland, T., Burnina, I., Sun, T., Caffry, I., Brown, M. E., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1290753 · Cited by 65
Datta‐Mannan, A., Chow, C.-K., Dickinson, C. D., Driver, D. A., Lu, J., Witcher, D. R., & Wroblewski, V. J. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.045864 · Cited by 64
Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Ramakrishna, V., Sundarapandiyan, K., Zhao, B., Bylesjö, M., Marsh, H. C., & Keler, T. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0080-2 · Cited by 64
Fab-based bispecific antibody formats with robust biophysical properties and biological activity
Wu, X., Sereno, A., Huang, F., Lewis, S. M., Lieu, R., Weldon, C. L., Torres, C., Fine, C., Batt, M. A., Fitchett, J. R., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1022694 · Cited by 63
Synthetic Antibody Libraries Focused Towards Peptide Ligands
Cobaugh, C. W., Almagro, J. C., Pogson, M., Iverson, B. L., & Georgiou, G. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.02.037 · Cited by 63
Structural diversity in a human antibody germline library
Teplyakov, A., Obmolova, G., Malia, T., Luo, J., Muzammil, S., Sweet, R. W., Almagro, J. C., & Gilliland, G. L. (2016) · mAbs · doi:10.1080/19420862.2016.1190060 · Cited by 62
Self-citationMorris, N. P., Peters, C., Montler, R. D., Hu, H., Curti, B. D., Urba, W. J., & Weinberg, A. D. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.02.004 · Cited by 61
Yin, S., Pastuskovas, C. V., Khawli, L. A., & Stults, J. T. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0860-z · Cited by 61
Jarantow, S. W., Bushey, B. S., Pardinas, J. R., Boakye, K., Lacy, E. R., Sanders, R., Sepúlveda, M. A., Moores, S. L., & Chiu, M. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.651653 · Cited by 61
Self-citationKim, J., Choi, D.-K., Shin, J.-Y., Shin, S.-M., Park, S.-W., Cho, H., & Kim, Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.066 · Cited by 61
PIGSPro: prediction of immunoGlobulin structures v2
Lepore, R., Olimpieri, P. P., Messih, M. A., & Tramontano, A. L. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx334 · Cited by 61
Structure-Guided Deimmunization of Therapeutic Proteins
Parker, A. S., Choi, Y., Griswold, K. E., & Bailey‐Kellogg, C. (2013) · Journal of Computational Biology · doi:10.1089/cmb.2012.0251 · Cited by 60
Jain, A. K., Olsen, H. S., Vyzasatya, R., Burch, E. E., Sakoda, Y., Mérigeon, E. Y., Cai, L., Lu, C., Tan, M. T., Tamada, K., et al. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4024 · Cited by 59
Lacy, S. E., Wu, C., Ambrosi, D. J., Hsieh, C.-M., Bose, S., Miller, R., Conlon, D., Tarcsa, E., Chari, R. V. J., Ghayur, T., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1026501 · Cited by 58
Antigen‐independent selection of stable intracellular single‐chain antibodies
der Maur, A. A., Escher, D., & Barberis, A. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03101-5 · Cited by 58
Balandin, T. G., Edelweiss, E. F., Андронова, Н. В., Treshalina, E. M., Sapozhnikov, A. M., & Deyev, S. M. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9329-2 · Cited by 58
Llama‐derived single‐domain intrabodies inhibit secretion of hepatitis B virions in mice†
Serruys, B., Houtte, F. V., Verbrugghe, P., Leroux-Roels, G. G., & Vanlandschoot, P. (2008) · Hepatology · doi:10.1002/hep.22609 · Cited by 58
Konno, Y., Kobayashi, Y., Takahashi, K. L., Takahashi, E., Sakae, S., Wakitani, M., Yamano, K., Suzawa, T., Yano, K., Ohta, T., et al. (2011) · Cytotechnology · doi:10.1007/s10616-011-9377-2 · Cited by 57
Engineering bispecific antibodies with defined chain pairing
Krah, S., Sellmann, C., Rhiel, L., Schröter, C. J., Dickgießer, S., Beck, J., Zielonka, S., Toleikis, L., Hock, B. M., Kolmar, H., et al. (2017) · New Biotechnology · doi:10.1016/j.nbt.2016.12.010 · Cited by 57
IgG Antibody 3D Structures and Dynamics
Jay, J. W., Bray, B., Qi, Y., Igbinigie, E., Wu, H., Li, J., & Ren, G. (2018) · Antibodies · doi:10.3390/antib7020018 · Cited by 57
Deimmunization of Monoclonal Antibodies
Jones, T. D., Crompton, L. J., Carr, F. J., & Baker, M. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-554-1_21 · Cited by 56
A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo
Atwal, J. K., Chen, Y., Chiu, C. W., Mortensen, D. L., Meilandt, W. J., liu, Y., Heise, C., Hoyte, K., Luk, W., Lu, Y., et al. (2013) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · Cited by 56
Schermeyer, M., Wöll, A. K., Kokke, B. P. A., Eppink, M. H. M., & Hubbuch, J. J. (2017) · mAbs · doi:10.1080/19420862.2017.1338222 · Cited by 56
Characterization of a new intrabody directed against the N-terminal region of human p53
Cohen, P. A., Mani, J. C., & Lane, D. P. (1998) · Oncogene · doi:10.1038/sj.onc.1202190 · Cited by 55
Vorup‐Jensen, T. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.06.003 · Cited by 55
New antibody approaches to lymphoma therapy
Suresh, T., Lee, L. X., Joshi, J., & Barta, S. K. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0058-4 · Cited by 55
Qureshi, O. S., Rowley, T. F., Junker, F., Peters, S. J., Crilly, S., Compson, J. E., Eddleston, A., Björkelund, H., Greenslade, K. J., Parkinson, M. D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17255-8 · Cited by 55
Metal ion interactions with mAbs: Part 1
Glover, Z. K., Basa, L. J., Moore, B. N., Laurence, J. S., & Sreedhara, A. (2015) · mAbs · doi:10.1080/19420862.2015.1062193 · Cited by 54
Senior, B. W., & Woof, J. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7792 · Cited by 54
Hayden, M. S., Linsley, P. S., Gayle, M. A., Bajorath, J., Brady, W., Norris, N. A., Fell, H. P., Ledbetter, J. A., & Gilliland, L. K. (1994) · PubMed · Cited by 53
Datta-Mannan, A., Witcher, D. R., Lu, J., & Wroblewski, V. J. (2012) · mAbs · doi:10.4161/mabs.4.2.19364 · Cited by 53
Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions
Bernett, M. J., Karki, S., Moore, G. L., Leung, I., Chen, H., Pong, E., Nguyen, D.-H. T., Jacinto, J. M., Zalevsky, J., Muchhal, U. S., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.12.046 · Cited by 53
Avidity confers FcγR binding and immune effector function to aglycosylated immunoglobulin G1
Nesspor, T., Raju, T. S., Chin, C., Vafa, O., & Brezski, R. J. (2012) · Journal of Molecular Recognition · doi:10.1002/jmr.2155 · Cited by 53
Glycosylation of Antibody Therapeutics: Optimisation for Purpose
Roy, J. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-407-0_13 · Cited by 53
The Fab portion of immunoglobulin G contributes to its binding to Fcγ receptor III
Yogo, R., Yamaguchi, Y., Watanabe, H., Yagi, H., Satoh, T., Nakanishi, M., Onitsuka, M., Ōmasa, T., Shimada, M., Maruno, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48323-w · Cited by 53
Targeting endogenous nuclear antigens by electrotransfer of monoclonal antibodies in living cells
Freund, G., Sibler, A., Desplancq, D., Oulad‐Abdelghani, M., Vigneron, M., Gannon, J., Regenmortel, M. H. V. V., & Weiss, É. (2013) · mAbs · doi:10.4161/mabs.25084 · Cited by 52
Detection of Histidine Oxidation in a Monoclonal Immunoglobulin Gamma (IgG) 1 Antibody
Amano, M., Kobayashi, N., Yabuta, M., Uchiyama, S., & Fukui, K. (2014) · Analytical Chemistry · doi:10.1021/ac501300m · Cited by 52
Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
Godar, M., de Haard, H., Blanchetot, C., & Rasser, J. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1428307 · Cited by 52
Shirai, H., Ikeda, K., Yamashita, K., Tsuchiya, Y., Sarmiento, J., Liang, S., Morokata, T., Mizuguchi, K., Higo, J., Standley, D. M., et al. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24591 · Cited by 51 · cited 2×
“The participants included Accelrys, Inc. [46], Chemical Computer Group (CCG) [47], Schrödinger [48], Jeff Gray’s lab at John Hopkins University [49] Macromoltek [50], Astellas Pharma/Osaka University [51], and Prediction of ImmunoGlobulin Structure (PIGS) [52,53].”
BackgroundGoenaga, A.-L., Zhou, Y., Legay, C., Bougherara, H., Huang, L., Liu, B., Drummond, D. C., Kirpotin, D. B., Auclair, C., Marks, J. D., et al. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.03.023 · Cited by 51
Nakanishi, T., Tsumoto, K., Yokota, A., Kondo, H., & Kumagai, I. (2008) · Protein Science · doi:10.1110/ps.073156708 · Cited by 51
Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination
Sharma, S. K., & Bagshawe, K. D. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1247802 · Cited by 51
rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs
Spirig, R., Campbell, I. K., Koernig, S., Chen, C., Lewis, B. J. B., Butcher, R. E., Muir, I. L., Taylor, S., Chia, J., Leong, D., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701171 · Cited by 51
Kinder, M., Greenplate, A. R., Strohl, W. R., Jordan, R. E., & Brezski, R. J. (2015) · mAbs · doi:10.1080/19420862.2015.1022692 · Cited by 50
Improving the species cross-reactivity of an antibody using computational design
Farady, C. J., Sellers, B. D., Jacobson, M. P., & Craik, C. S. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.005 · Cited by 50
Antibody–Enzyme Fusion Proteins for Cancer Therapy
Andrady, C., Sharma, S. K., & Chester, K. A. (2011) · Immunotherapy · doi:10.2217/imt.10.90 · Cited by 50
Effect of high mannose glycan pairing on IgG antibody clearance
Liu, D., & Flynn, G. C. (2016) · Biologicals · doi:10.1016/j.biologicals.2016.02.003 · Cited by 49
IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?
Kronimus, Y., Dodel, R. C., Galuska, S. P., & Neumann, S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.10.006 · Cited by 49
Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody
Zheng, S., Moores, S. L., Jarantow, S. W., Pardinas, J. R., Chiu, M. L., Zhou, H., & Wang, W. (2016) · mAbs · doi:10.1080/19420862.2015.1136762 · Cited by 48
Self-citationImproving Antibody Binding Affinity and Specificity for Therapeutic Development
Boström, J., Lee, C. V., Haber, L., & Fuh, G. (2008) · Methods in molecular biology · doi:10.1007/978-1-59745-554-1_19 · Cited by 48
Zhong, X., Ma, W., Meade, C., Tam, A. S. P., Llewellyn, E., Cornell, R. J., Cote, K., Scarcelli, J. J., Marshall, J. K., Tzvetkova, B., et al. (2018) · Biotechnology Progress · doi:10.1002/btpr.2724 · Cited by 48
Humanization of antibodies using a statistical inference approach
Clavero-Álvarez, A., Di Mambro, T., Perez-Gaviro, S., Magnani, M., & Bruscolini, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-32986-y · Cited by 47
Humanisation of monoclonal antibodies for therapy.
Gorman, S. D., & Clark, M. (1990) · PubMed · Cited by 47
Phillips, J. J., Buchanan, A. G., Andrews, J. L., Chodorge, M., Sridharan, S., Mitchell, L., Burmeister, N., Kippen, A. D., Vaughan, T. J., Higazi, D. R., et al. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b04158 · Cited by 45
Single domain antibodies for the knockdown of cytosolic and nuclear proteins
Böldicke, T. W. (2017) · Protein Science · doi:10.1002/pro.3154 · Cited by 45
Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions
Kinder, M., Greenplate, A. R., Grugan, K. D., Soring, K. L., Heeringa, K., McCarthy, S. G., Bannish, G., Perpetua, M., Lynch, F., Jordan, R. E., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.486142 · Cited by 44
The Withdrawal of Drugs for Commercial Reasons
Prasad, V. K. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.5756 · Cited by 44
Wirth, M., Heidenreich, A., Gschwend, J. E., Gil, T., Zastrow, S., Laniado, M., Gerloff, J., Zühlsdorf, M., Mordenti, G., Uhl, W., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.05.051 · Cited by 43
Glutamine deamidation of a recombinant monoclonal antibody
Liu, H., Gaza‐Bulseco, G., & Chumsae, C. M. (2008) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.3831 · Cited by 43
A universal strategy for stable intracellular antibodies
Loewenstein, S., Zfania, R., Hyland, S. N., Wels, W. S., & Benhar, I. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.05.004 · Cited by 43
Senior, B. W., & Woof, J. M. (2005) · Infection and Immunity · doi:10.1128/iai.73.3.1515-1522.2005 · Cited by 43
Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies
Kim, J. M., & Ashkenazi, A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20131625 · Cited by 43
Leveraging SBDD in Protein Therapeutic Development: Antibody Engineering
Gilliland, G. L., Luo, J., Vafa, O., & Almagro, J. C. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-520-6_14 · Cited by 43
Self-citationFab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding
Davé, E., Adams, R., Zaccheo, O., Carrington, B., Compson, J. E., Dugdale, S., Airey, M., Malcolm, S., Hailu, H., Wild, G., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1210747 · Cited by 43
Brezski, R. J., Greenplate, A. R., Strake, B., & Jordan, R. E. (2011) · mAbs · doi:10.4161/mabs.3.6.18119 · Cited by 42
Bönisch, M., Sellmann, C., Maresch, D., Halbig, C., Becker, S., Toleikis, L., Hock, B. M., & Rüker, F. (2017) · Protein Engineering Design and Selection · doi:10.1093/protein/gzx044 · Cited by 42
Alam, M. E., Barnett, G. V., Slaney, T. R., Starr, C. G., Das, T. K., & Tessier, P. M. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b01311 · Cited by 42
Glycosylation of Natural and Recombinant Antibody Molecules
Jefferis, R. (2005) · Advances in experimental medicine and biology · doi:10.1007/0-387-25515-x_26 · Cited by 41
Molecular Dynamics of Hinge-Bending Motion of IgG Vanishing with Hydrolysis by Papain
Hayashi, Y., Miura, N., Isobe, J., Shinyashiki, N., & Yagihara, S. (2000) · Biophysical Journal · doi:10.1016/s0006-3495(00)76356-9 · Cited by 41
Kabat, E. A., Wu, T. T., & Bilofsky, H. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.2.617 · Cited by 41
Narayanan, A., Sellers, B. D., & Jacobson, M. P. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.03.043 · Cited by 41
Park, Y., Pardon, E., Wu, M., Steyaert, J., & Hol, W. G. J. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr867 · Cited by 41
Atomic resolution model of the antibody Fc interaction with the complement C1q component
Schneider, S. C., & Zacharias, M. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.02.111 · Cited by 41
A practical approach for intracellular protein delivery
Weill, C. O., Biri, S., Adib, A., & Erbacher, P. (2007) · Cytotechnology · doi:10.1007/s10616-007-9102-3 · Cited by 40
CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy
Li, B., Xu, L., Pi, C., Yin, Y., Xie, K., Tao, F., Li, R., Gu, H., & Fang, J. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1380142 · Cited by 40
Chung, S., Tian, J., Tan, Z., Chen, J., Zhang, N., Huang, Y., Vandermark, E., Lee, J. C., Borys, M., & Li, Z. J. (2019) · mAbs · doi:10.1080/19420862.2018.1537533 · Cited by 40
Two-in-One antibodies with dual action Fabs
Eigenbrot, C. W., & Fuh, G. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.04.015 · Cited by 39
Tam, S. H., McCarthy, S. G., Armstrong, A., Somani, S., Wu, S., Liu, X., Gervais, A., Ernst, R., Saro, D., Decker, R., et al. (2017) · Antibodies · doi:10.3390/antib6030012 · Cited by 39
Self-citationKiefer, J. D., & Neri, D. (2016) · Immunological Reviews · doi:10.1111/imr.12391 · Cited by 38
LC-MS characterization and purity assessment of a prototype bispecific antibody
Woods, R. J., Xie, M. H., von Kreudenstein, T. S., Ng, G., & Dixit, S. B. (2013) · mAbs · doi:10.4161/mabs.25488 · Cited by 37
Wheeler, Y. Y., Kute, T. E., Willingham, M. C., Chen, S., & Sane, D. C. (2003) · The FASEB Journal · doi:10.1096/fj.02-0942fje · Cited by 37
Egan, P., & Reagan, J. L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s150807 · Cited by 37
Yanaka, S., Yogo, R., Inoue, R., Sugiyama, M., Itoh, S., Okumura, H., Miyanoiri, Y., Yagi, H., Satoh, T., Yamaguchi, T., et al. (2019) · Antibodies · doi:10.3390/antib8030039 · Cited by 37
Bogen, J. P., Hinz, S. C., Grzeschik, J., Ebenig, A., Krah, S., Zielonka, S., & Kolmar, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01892 · Cited by 37
Lehmann, A., Wixted, J. H. F., Shapovalov, M. V., Röder, H., Dunbrack, R. L., & Robinson, M. K. (2015) · mAbs · doi:10.1080/19420862.2015.1088618 · Cited by 36
Xiang, J., Sha, Y., Jia, Z., et al. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0560 · Cited by 36
Jetha, A., Thorsteinson, N., Jmeian, Y., Jeganathan, A., Giblin, P. A., & Fransson, J. (2018) · mAbs · doi:10.1080/19420862.2018.1475871 · Cited by 36
Kim, Y., Bae, J., Shin, T.-H., Kang, S. H., Jeong, M., Han, Y., Park, J., Kim, S.-K., & Kim, Y. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.016 · Cited by 35
Automated antibody structure prediction using Accelrys tools: Results and best practices
Fasnacht, M., Butenhof, K. J., Lamy, A., Hernandez-Guzman, F. G., Huang, H., & Yan, L. (2014) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24604 · Cited by 35
Use of mutation spectra analysis software
Rogozin, I. B., Kondrashov, F. A., & Glazko, G. V. (2001) · Human Mutation · Cited by 35
Olivier, S., Jacoby, M., Brillon, C., Bouletreau, S., Mollet, T., Nerrière, O., Angel, A., Danet, S., Souttou, B., Guéhenneux, F., et al. (2010) · mAbs · doi:10.4161/mabs.12350 · Cited by 35
Clinical Ramifications of the MHC Family Fc Receptor FcRn
Roopenian, D. C., & Sun, V. Z. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9458-6 · Cited by 35
Zhang, D., Armstrong, A. A., Tam, S. H., McCarthy, S. G., Luo, J., Gilliland, G. L., & Chiu, M. L. (2017) · mAbs · doi:10.1080/19420862.2017.1358838 · Cited by 35
Self-citationLandolfi, N. F., Thakur, A. B., Fu, H., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1748 · Cited by 34
Colley, C. S., Popovic, B., Sridharan, S., Debreczeni, J. E., Hargeaves, D., Fung, M. S. C., An, L., Edwards, B. M., Arnold, J., England, E., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1384892 · Cited by 34
Use of In Vitro Systems To Model In Vivo Degradation of Therapeutic Monoclonal Antibodies
Yang, N., Tang, Q., Hu, P., & Lewis, M. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b00183 · Cited by 34
Barnett, G. V., Balakrishnan, G., Chennamsetty, N., Hoffman, L., Bongers, J., Tao, L., Huang, Y., Slaney, T., Das, T. K., Leone, A., et al. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.12.027 · Cited by 33
Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors
Derebe, M. G., Nanjunda, R. K., Gilliland, G. L., Lacy, E. R., & Chiu, M. L. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.02.006 · Cited by 33
Self-citationRowley, T. F., Peters, S. J., Aylott, M. C., Griffin, R., Davies, N. L., Healy, L. J., Cutler, R. M., Eddleston, A., Pither, T. L., Sopp, J. M., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0149-9 · Cited by 33
The Role of Cell‐Surface Receptors in the Transport and Catabolism of Immunoglobulins
Waldmann, T. A., & Jones, E. A. (1973) · Novartis Foundation symposium · doi:10.1002/9780470719923.ch2 · Cited by 31
Lee, C. V., Koenig, P. S., & Fuh, G. (2014) · mAbs · doi:10.4161/mabs.28483 · Cited by 30
Koenitzer, J. D., Sieron, A., Wacker, A., & Enenkel, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145633 · Cited by 30
Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding
Zwolak, A., Leettola, C. N., Tam, S. H., Goulet, D. R., Derebe, M. G., Pardinas, J. R., Zheng, S., Decker, R., Emmell, E., & Chiu, M. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-15748-0 · Cited by 30
Self-citationSelective Tryptophan Oxidation of Monoclonal Antibodies: Oxidative Stress and Modeling Prediction
Pavon, J. A., Xiao, L., Li, X., Zhao, J., Aldredge, D. L., Dank, E., Fridman, A., & Liu, Y. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.8b04768 · Cited by 30
Laffly, E., Pelat, T., Cédrone, F., Blésa, S., Bedouelle, H., & Thullier, P. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.03.045 · Cited by 29
Babor, M., Mandell, D. J., & Kortemme, T. (2011) · Protein Science · doi:10.1002/pro.632 · Cited by 29
A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth
Jia, X., Wang, W., Xu, Z., Wang, S., Wang, T., Wang, M., & Wu, M. (2016) · Scientific Reports · doi:10.1038/srep27985 · Cited by 29
Fossati, M., Buzzonetti, A., Monego, G., Catzola, V., Scambia, G., Fattorossi, A., & Battaglia, A. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.06.003 · Cited by 28
Lamdán, H., Gavilondo, J., Muñoz, Y., Pupo, A., Huerta, V., Musacchio, A., Pérez, L., Ayala, M., Rojas, G., Balint, R. F., et al. (2013) · Molecular BioSystems · doi:10.1039/c3mb70136k · Cited by 27
Hu, W., Chau, D., Wu, J., Jager, S., & Nagata, L. P. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.01.034 · Cited by 27
Populations of Metal-Glycan Structures Influence MS Fragmentation Patterns
Zhu, F., Glover, M. S., Shi, H., Trinidad, J. C., & Clemmer, D. E. (2014) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-014-1000-2 · Cited by 27
A Novel Bispecific Antibody, S-Fab, Induces Potent Cancer Cell Killing
Li, L., He, P., Zhou, C., Jing, L., Dong, B., Chen, S., Zhang, N., Liu, Y., Miao, J. H., Wang, Z., et al. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000099 · Cited by 27
Protein Sequence and Structure Analysis of Antibody Variable Domains
Martin, A. C. R. (2010) · Springer eBooks · doi:10.1007/978-3-642-01147-4_3 · Cited by 27
Functional knockdown of VCAM-1 at the posttranslational level with ER retained antibodies
Strebe, N., Guse, A., Schüngel, M., Schirrmann, T., Hafner, M., Jostock, T., Hust, M., Müller, W., & Dübel, S. (2008) · Journal of Immunological Methods · doi:10.1016/j.jim.2008.10.012 · Cited by 26
Ma, B., Zhao, J., & Nussinov, R. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.05.040 · Cited by 26
Role of lysosomes in cancer therapy
Halaby, R. (2015) · Research and Reports in Biology · doi:10.2147/rrb.s83999 · Cited by 25
CD20‐Specific Immunoligands Engaging NKG2D Enhance γδ T Cell‐Mediated Lysis of Lymphoma Cells
Peipp, M., Wesch, D., Oberg, H., Lutz, S., Muskulus, A., van de Winkel, J. G. J., Parren, P. W. H. I., Burger, R., Humpe, A., Kabelitz, D., et al. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12581 · Cited by 25
Development of scoring functions for antibody sequence assessment and optimization
Seeliger, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076909 · Cited by 24
The glycosylation of antibody molecules: functional significance.
Jefferis, R. (1993) · PubMed · Cited by 24
Comprehensive manipulation of glycosylation profiles across development scales
Loebrich, S., Clark, E. C., Ladd, K., Takahashi, S., Brousseau, A., Kitchener, S., Herbst, R., & Ryll, T. (2018) · mAbs · doi:10.1080/19420862.2018.1527665 · Cited by 24
Kontermann, R. E. (2011) · Springer eBooks · doi:10.1007/978-3-642-20910-9 · Cited by 24
The Protein-Protein Interface Evolution Acts in a Similar Way to Antibody Affinity Maturation
Li, B., Zhao, L., Wang, C., Guo, H., Wu, L., Zhang, X., Qian, W., Wang, H., & Guo, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.076547 · Cited by 23
Fc Receptors as Targets for Immunotherapy
Rouard, H., Tamasdan, S., Moncuit, J., Moutel, S., Michon, J. M., Fridman, W. H., & Teillaud, J. (1997) · International Reviews of Immunology · doi:10.3109/08830189709045707 · Cited by 23
Cymer, F., Thomann, M., Wegele, H., Avenal, C., Schlothauer, T., Gygax, D., & Beck, H. (2017) · Biologicals · doi:10.1016/j.biologicals.2017.09.006 · Cited by 23
Rosenberg, Y. J., Lewis, G. K., Montefiori, D. C., LaBranche, C. C., Lewis, M. G., Urban, L. A., Lees, J. P., Mao, L., & Jiang, X. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212649 · Cited by 23
Engineering an anti-CD52 antibody for enhanced deamidation stability
Qiu, H., Wei, R. R., Jaworski, J. A., Boudanova, E., Hughes, H., VanPatten, S., Lund, A. L., Day, J., Zhou, Y., McSherry, T., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1631117 · Cited by 22
TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cellsin vitroandin vivo
Piao, X., Ozawa, T., Hamana, H., Shitaoka, K., Jin, A., Kishi, H., & Muraguchi, A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1131380 · Cited by 21
Henry, K. A., Kim, D. Y., Kandalaft, H., Lowden, M. J., Yang, Q., Schrag, J. D., Hussack, G., MacKenzie, C. R., & Tanha, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01759 · Cited by 21
Fonseca, M. H. G., Furtado, G. P., Bezerra, M. R. L., Pontes, L. Q., & Fernandes, C. F. C. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.07.141 · Cited by 21
Tempest, P. R., White, P., Buttle, M., Carr, F. J., & Harris, W. J. (1995) · International Journal of Biological Macromolecules · doi:10.1016/0141-8130(95)93516-z · Cited by 20
Automated Aufbau of antibody structures from given sequences using Macromoltek's SmrtMolAntibody
Berrondo, M., Kaufmann, S., & Berrondo, M. (2014) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24595 · Cited by 19
Koenig, P. S., Sanowar, S., Lee, C. V., & Fuh, G. (2017) · mAbs · doi:10.1080/19420862.2017.1337618 · Cited by 19
Elucidation of potential sites for antibody engineering by fluctuation editing
Yanaka, S., Moriwaki, Y., Tsumoto, K., & Sugase, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-10246-9 · Cited by 19
Protein Sequence and Structure Analysis of Antibody Variable Domains
Martin, A. C. R. (2001) · Springer eBooks · doi:10.1007/978-3-662-04605-0_31 · Cited by 18
Selection and characterization of cell binding and internalizing phage antibodies
Zhou, Y., Lequn, Z., & Marks, J. D. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.05.007 · Cited by 18
Kim, J., Park, J.-Y., Shin, S., Park, S.-W., Jun, S.-Y., Hong, J.-S., Choi, D.-K., & Kim, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.07.008 · Cited by 18
Influence of the bispecific antibody IgG subclass on T cell redirection
Kapelski, S., Cleiren, E., Attar, R. M., Philippar, U., Häsler, J., & Chiu, M. L. (2019) · mAbs · doi:10.1080/19420862.2019.1624464 · Cited by 18
Self-citationVillani, M. E., Morea, V., Consalvi, V., Chiaraluce, R., Desiderio, A., Benvenuto, E., & Donini, M. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.01.016 · Cited by 17
Design and validation of a synthetic VH repertoire with tailored diversity for protein recognition
Almagro, J. C., Quintero‐Hernández, V., Ortíz-León, M., Velandia, A. E., Smith, S. L., & Becerril, B. (2006) · Journal of Molecular Recognition · doi:10.1002/jmr.796 · Cited by 17
Fc Engineering to Improve the Function of Therapeutic Antibodies
Mimoto, F., Kuramochi, T., Katada, H., Igawa, T., & Hattori, K. (2016) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201017666160824161854 · Cited by 17
Lord, D. M., Jaworski, J. A., Honey, D. M., Best, A., Park, A., Wei, R. R., & Qiu, H. (2018) · mAbs · doi:10.1080/19420862.2018.1426421 · Cited by 17
Grossman, I., Ilani, T., Fleishman, S. J., & Fass, D. (2016) · Protein Engineering Design and Selection · doi:10.1093/protein/gzv067 · Cited by 14
Goulet, D. R., Orcutt, S. J., Zwolak, A., Rispens, T., Labrijn, A. F., de Jong, R. N., Atkins, W. M., & Chiu, M. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000303 · Cited by 14
Self-citationŠkrlj, N., Vranac, T., Popović, M., Šerbec, V. Č., & Dolinar, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015783 · Cited by 13
Vauquelin, G., Bricca, G., & Liefde, I. V. (2013) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12052 · Cited by 13
Zwolak, A., Armstrong, A. A., Tam, S. H., Pardinas, J. R., Goulet, D. R., Zheng, S., Brosnan, K., Emmell, E., Luo, J., Gilliland, G. L., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1375639 · Cited by 13
Self-citationStructural insights into humanization of anti-tissue factor antibody 10H10
Teplyakov, A., Obmolova, G., Malia, T., Raghunathan, G., Martinez, C., Fransson, J., Edwards, W., Connor, J., Husovsky, M., Beck, H., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1412026 · Cited by 13
Self-citationNon‐covalent interactions between Fab and Fc regions in immunoglobulin G molecules
Kilár, F., & Závodszky, P. (1987) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1987.tb10541.x · Cited by 12
Affinity maturation of a CDR3-grafted VHH using in silico analysis and surface plasmon resonance
Inoue, H., Suganami, A., Ishida, I., Tamura, Y., & Maeda, Y. (2013) · The Journal of Biochemistry · doi:10.1093/jb/mvt058 · Cited by 12
Humanized antibody neutralizing 2009 pandemic H1N1 virus
Shembekar, N., Mallajosyula, V. V. A., Chaudhary, P., Upadhyay, V., Varadarajan, R., & Sk, G. (2014) · Biotechnology Journal · doi:10.1002/biot.201400083 · Cited by 11
Schlapschy, M., Fogarasi, M., Gruber, H., Gresch, O., Schafer, C., Aguib, Y., & Skerra, A. (2008) · Protein Engineering Design and Selection · doi:10.1093/protein/gzn066 · Cited by 10
Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
Escobar-Cabrera, E., Lario, P. I., Baardsnes, J., Schrag, J. D., Durocher, Y., & Dixit, S. B. (2017) · Antibodies · doi:10.3390/antib6020007 · Cited by 10
Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy
Nordin, M. C., & Teow, S. (2018) · Molecules · doi:10.3390/molecules23020335 · Cited by 10
CAT192 Fab Insertion Mutant H2/L2
Lord, D. M., & Wei, R. R. (2017) · Worldwide Protein Data Bank · doi:10.2210/pdb6ao0/pdb · Cited by 9
Douillard, P., Freissmuth, M., Antoine, G., Thiele, M., Fleischanderl, D., Matthiessen, P., Voelkel, D., Kerschbaumer, R. J., Scheiflinger, F., & Sabarth, N. (2019) · Antibodies · doi:10.3390/antib8030046 · Cited by 9
Maximizing the potency of an anti-TLR4 monoclonal antibody by exploiting proximity to Fcγ receptors
Loyau, J., Malinge, P., Daubeuf, B., Shang, L., Elson, G., Kosco‐Vilbois, M. H., Fischer, N., & Rousseau, F. (2014) · mAbs · doi:10.4161/19420862.2014.975098 · Cited by 8
Back-to-Germline (B2G) Procedure for Antibody Devolution
Schrade, A., Bujotzek, A., Spick, C., Wagner, M., Goerl, J., Wezler, X., Georges, G. J., Kontermann, R. E., & Brinkmann, U. (2019) · Antibodies · doi:10.3390/antib8030045 · Cited by 7
Proceedings: Selective oxidation of methionine residues in proteins.
Schechter, Y., Burstein, Y., & Patchornik, A. (1975) · PubMed · Cited by 4
Cited by
Olsen, T. H., Boyles, F., & Deane, C. M. (2022) · Protein Science · doi:10.1002/pro.4205 · Cited by 319
ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins
Abanades, B., Wong, W. K., Boyles, F., Georges, G., Bujotzek, A., & Deane, C. M. (2023) · Communications Biology · doi:10.1038/s42003-023-04927-7 · Cited by 298
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
AFsample: improving multimer prediction with AlphaFold using massive sampling
Wallner, B. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad573 · Cited by 164
ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation
Abanades, B., Georges, G., Bujotzek, A., & Deane, C. M. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac016 · Cited by 157
Metadata
- Authors
- Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L.
- Venue
- Antibodies
- Publisher
- MDPI AG
- Published
- 2019-12-03
- Volume
- 8
- Issue
- 4
- Pages
- 55
- ISSN
- 2073-4468 (ISSN-L)
- OpenAlex
- W2993866869
- Cited by
- 638
- References
- 560
- FWCI
- 28.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.